Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-22
DOI
10.1038/s41598-021-94431-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy
- (2020) Jiaqi Yao et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
- (2020) Konstantinos Papamichael et al. CURRENT OPINION IN RHEUMATOLOGY
- Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study
- (2020) Nienke Z. Borren et al. DIGESTIVE DISEASES AND SCIENCES
- A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies
- (2019) Marten Beeg et al. Scientific Reports
- Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab
- (2018) B. Gorovits et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis
- (2018) Amanda Ricciuto et al. Journal of Crohns & Colitis
- Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study
- (2018) Henit Yanai et al. Journal of Crohns & Colitis
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- (2017) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
- (2017) Mariam Aguas Peris et al. INFLAMMATORY BOWEL DISEASES
- Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
- (2017) Liming Liu Protein & Cell
- A Systematic Review on Infliximab and Adalimumab Drug Monitoring
- (2016) Filipa Silva-Ferreira et al. INFLAMMATORY BOWEL DISEASES
- Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies
- (2016) Casper Steenholdt et al. INFLAMMATORY BOWEL DISEASES
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
- (2016) Fernando Gomollón et al. Journal of Crohns & Colitis
- Theoretical approximations and experimental extinction coefficients of biopharmaceuticals
- (2015) Mariana P. Miranda-Hernández et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility
- (2015) Meenu Wadhwa et al. BIOLOGICALS
- Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
- (2015) B. Rup et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
- (2014) Niels Vande Casteele et al. GUT
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment
- (2013) Hirotsugu Imaeda et al. JOURNAL OF GASTROENTEROLOGY
- Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohnʼs Disease
- (2013) Casper Steenholdt et al. THERAPEUTIC DRUG MONITORING
- Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
- (2012) Narendra Chirmule et al. AAPS Journal
- Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
- (2012) N. Vande Casteele et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
- (2012) Shui-Long Wang et al. JOURNAL OF IMMUNOLOGICAL METHODS
- The safety and side effects of monoclonal antibodies
- (2010) Trevor T. Hansel et al. NATURE REVIEWS DRUG DISCOVERY
- Predicting the response to infliximab from trough serum levels
- (2009) P. Rutgeerts et al. GUT
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now